Hudson Bay Capital Management
DAWN

Hudson Bay Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Hudson Bay Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.4M Sell
670,000
-1,030,000
-61% -$14.5M 0.05% 242
2025
Q4 		$15.8M Buy
1,700,000
+380,000
+29% +$3.17M 0.05% 256
2025
Q3 		$9.31M Buy
1,320,000
+23,300
+2% +$160K 0.03% 375
2025
Q2 		$8.43M Buy
1,296,700
+146,300
+13% +$1.01M 0.03% 398
2025
Q1 		$9.12M Buy
1,150,400
+230,292
+25% +$2.48M 0.03% 425
2024
Q4 		$11.7M Buy
920,108
+200,000
+28% +$2.78M 0.04% 334
2024
Q3 		$10M Buy
720,108
+165,000
+30% +$2.35M 0.04% 288
2024
Q2 		$7.65M Buy
555,108
+445,108
+405% +$6.51M 0.04% 288
2024
Q1 		$1.82M Buy
110,000
+30,000
+38% +$449K 0.01% 470
2023
Q4 		$1.17M Buy
+80,000
New +$970K 0.01% 506

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Hudson Bay Capital Management's DAWN Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Day One Biopharmaceuticals (DAWN) stake by 61% in Q1 2026, selling an estimated $14.5M and leaving 670,000 shares worth $14.4M. The position accounts for 0.05% of the portfolio, ranked #242.

Hudson Bay Capital Management first reported a position in DAWN in Q4 2023 and has held it in 10 quarters since. The position peaked at $15.8M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Hudson Bay Capital Management held 670,000 shares of Day One Biopharmaceuticals worth $14.4M as of Q1 2026.
  • Hudson Bay Capital Management sold 1,030,000 Day One Biopharmaceuticals shares in Q1 2026, an estimated $14.5M.
  • Day One Biopharmaceuticals made up 0.05% of Hudson Bay Capital Management's portfolio in Q1 2026, its #242 holding.
  • Hudson Bay Capital Management first reported a position in Day One Biopharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Hudson Bay Capital Management's Day One Biopharmaceuticals position peaked at $15.8M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.